Published Date: 12 Aug 2023
The FDA's approval comes after a number of other multiple myeloma medications that had previously received accelerated FDA approval were taken off the market.
Read Full NewsEnhancing Comprehensive Biomarker Testing and Biomarker-Directed Treatment Selection
Advancing Care in ES-SCLC: Personalized Strategies, New Therapies, and Real-World Insights
Belzutifan and pembrolizumab together reduced the risk of disease recurrence or death
Capivasertib plus abiraterone combination lands indication for PTEN-deficient tumors
"Combinations represent additional options for early-line treatment," researcher says
The bispecific T-cell engager also reduced toxicity in newly diagnosed kids
A combination of clinician and patient prompts worked best, but talks remained infrequent
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation